Point-of-Care Intrapartum Group B Streptococcus Molecular Screening Effectiveness and Costs

被引:19
作者
El Helali, Najoua
Habibi, Fakher
Azria, Elie
Giovangrandi, Yves
Autret, Fanny
Durand-Zaleski, Isabelle
Le Monnier, Alban
机构
[1] Univ Paris Sud Saday, France EA4043 Unite Bacteries Pathogens & Sante, Grp Hosp Paris St Joseph, Serv Microbiol Clin, Chalenay Malabry, France
[2] Grp Hosp Paris St Joseph, Serv Neonatol, Paris, France
[3] Grp Hosp Paris St Joseph, Serv Gynecol Obstet, Paris, France
[4] Paris Descartes Univ, DHU Risk Pregnancy, Obstet Neonatal & Pediat Epidemiol Res Team EPOPe, France UMR1153, Paris, France
[5] Univ Paris Est Criteil, ECEVE, Hop Dieu, AP HP,Unite Rech Clin Econ Sante Ile de France,UM, Paris, France
关键词
DISEASE; ERA;
D O I
10.1097/AOG.0000000000003057
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To assess outcomes and costs associated with around-the-clock point-of-care intrapartum group B streptococcus (GBS) polymerase chain reaction (PCR) screening. METHODS: Intrapartum PCR screening was implemented in 2010. Intrapartum PCR was compared with antenatal culture screening in an uncontrolled, single institution, preintervention and postintervention study. The study periods included 4 years before and 6 years after the intervention, commencing in 2006 and concluding in 2015. The primary outcome measure was rate of early-onset neonatal GBS disease. Secondary outcomes included length of stay, days of antibiotics, and costs. RESULTS: During the 4 years of antenatal culture screening, 11,226 deliveries were recorded compared with 18,835 in the 6 years of intrapartum GBS PCR screening, corresponding to 11,818 and 18,980 live births, respectively. During the antenatal culture period, 3.8% of term deliveries did not undergo GBS testing compared with 0.1% during the intrapartum PCR period (P<.001). Between the two periods, the rate of proven early-onset GBS disease cases decreased from 1.01/1,000 to 0.21/1,000 (P=.026) and probable early-onset GBS disease cases from 2.8/1,000 to 0.73/1,000 (P<.001); the risk ratio for both was 0.25, 95% CI (0.14-0.43). Total days of hospital and antibiotic therapy for early-onset GBS disease declined by 64% and 60%, respectively, with no significant difference for average length of stay or antibiotic duration preintervention and postintervention. The yearly cost of delivery and treatment of newborns with GBS infection was reduced from $41,875 +/- 6,823 to $11,945 +/- 10,303 (P<.001). The estimated extra cost to avoid one early-onset GBS disease was $5,819. CONCLUSION: Point-of-care intrapartum GBS PCR screening was associated with a significant decrease in the rate of early-onset GBS disease and antibiotic use in newborns. The additional PCR costs were offset in part by the reduction in early-onset GBS disease treatment costs.
引用
收藏
页码:276 / 281
页数:6
相关论文
共 14 条
  • [1] [Anonymous], 2010, MMWR-MORBID MORTAL W
  • [2] The spectrum of perinatal group B streptococcal disease
    Baker, Carol J.
    [J]. VACCINE, 2013, 31 : D3 - D6
  • [3] PREVENTION OF EARLY-ONSET NEONATAL GROUP-B STREPTOCOCCAL DISEASE WITH SELECTIVE INTRAPARTUM CHEMOPROPHYLAXIS
    BOYER, KM
    GOTOFF, SP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (26) : 1665 - 1669
  • [4] Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference
    Di Renzo, G. C.
    Melin, P.
    Berardi, A.
    Blennow, M.
    Carbonell-Estrany, X.
    Donzelli, G. P.
    Hakansson, S.
    Hod, M.
    Hughes, R.
    Kurtzer, M.
    Poyart, C.
    Shinwell, E.
    Stray-Pedersen, B.
    Wielgos, M.
    El Helai, N.
    [J]. JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2015, 28 (7-8) : 766 - 782
  • [5] Cost and Effectiveness of Intrapartum Group B Streptococcus Polymerase Chain Reaction Screening for Term Deliveries
    El Helali, Najoua
    Giovangrandi, Yves
    Guyot, Kathleen
    Chevet, Karine
    Gutmann, Laurent
    Durand-Zaleski, Isabelle
    [J]. OBSTETRICS AND GYNECOLOGY, 2012, 119 (04) : 822 - 829
  • [6] Diagnostic Accuracy of a Rapid Real-Time Polymerase Chain Reaction Assay for Universal Intrapartum Group B Streptococcus Screening
    El Helali, Najoua
    Nguyen, Jean-Claude
    Ly, Aicha
    Giovangrandi, Yves
    Trinquart, Ludovic
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (03) : 417 - 423
  • [7] Goodman J R, 1997, Infect Dis Obstet Gynecol, V5, P237, DOI 10.1155/S1064744997000409
  • [8] Perinatal screening for group B streptococci: Cost-benefit analysis of rapid polymerase chain reaction
    Haberland, CA
    Benitz, WE
    Sanders, GD
    Pietzsch, JB
    Yamada, S
    Nguyen, L
    Garber, AM
    [J]. PEDIATRICS, 2002, 110 (03) : 471 - 480
  • [9] Incidence and distribution of pathogens in early-onset neonatal sepsis in the era of antenatal antibiotics
    Kuhn, Pierre
    Dheu, Celine
    Bolender, Chantal
    Chognot, Didier
    Keller, Laurence
    Demil, Houria
    Donato, Lionel
    Langer, Bruno
    Messer, Jean
    Astruc, Dominique
    [J]. PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2010, 24 (05) : 479 - 487
  • [10] Assessment of Intrapartum Antibiotic Prophylaxis for the Prevention of Early-onset Group B Streptococcal Disease
    Lin, Feng-Ying C.
    Weisman, Leonard E.
    Azimi, Parvin
    Young, Amy E.
    Chang, Kathleen
    Cielo, Mikhaela
    Moyer, Patricia
    Troendle, James F.
    Schneerson, Rachel
    Robbins, John B.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (09) : 759 - 763